Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

Genome Plasmid

University Of Edinburgh

This public procurement record has 2 releases in its history.

Award

31 Mar 2026 at 01:00

PCS Notice - Website Contract Award Notice
Tender

17 Jun 2025 at 01:00

PCS Notice - Website Contract Notice
Summary of the contracting process

The University of Edinburgh has successfully concluded a public procurement process, titled "Genome Plasmid," under the industry category of Education. The contract aims to advance a clinical trial for treating a rare genetic disease causing progressive dementia in children. This involves procuring a specially formulated plasmid to meet FDA standards, crucial for manufacturing a lentiviral vector. The procurement process, which involved an open procedure, has reached the award stage with a notable deadline from 1 July 2025, for bid submissions. The goods will be delivered to Los Angeles, USA, directly to the University of California Los Angeles, a partner in this research project.

This tender offers significant opportunities for businesses specialising in genetic and biotechnology research and product development, particularly those with FDA approval experience. Companies with expertise in producing high-quality plasmids for clinical trials can find substantial opportunity for growth. Large-scale operations with a strong track record in FDA approvals and quality management systems like 'GMP' will be well-suited to compete in similar future tenders, given the requirements set by the University of Edinburgh for this project. The procurement's open nature fosters competitive bidding, potentially offering further project scope expansion through additional orders.

How relevant is this notice?

Notice Information

Notice Title

Genome Plasmid

Notice Description

We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles.

Lot Information

Lot 1

We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles. This will require the following QC to be performed: - Appearance - Clear, Colorless, No Visible Particulates upon visual inspection - A260:280 - 1.7-2.0 measured by Spectrophotometer - Concentration - 1.0 - 1.1 mg/ml (0.95-1.14mg/ml) measured by Spectrophotometer - Endotoxin - <30 EU/mg measured by Endosafe(r) PTS - DNA Homogeneity - >=90% All Supercoiled Forms analysed by Agarose Gel Electrophoresis - Residual RNA - None Detected @ 1.0mg load analysed by Agarose Gel Electrophoresis and Plasmid Safe(tm) Assay - Residual ssDNA - None Detected @ 1.0mg load analysed by Agarose Gel Electrophoresis and Plasmid Safe(tm) Assay - Residual Chromosomal DNA - None Detected @ 1.0mg load analysed by Agarose Gel Electrophoresis and Plasmid Safe(tm) Assay - Residual Linear DNA - <3% analysed by Plasmid Safe(tm) Assay and Linear DNA Assay - Identity - Consistent with Provided Information for 4 Restriction Reactions with no Discrepancies analysed by Restriction Digest and Research Primer Walking Sequencing - Protein - Reported measured by Micro BCA(tm) - pH of Final Product - 7.5-8.5 measured by pH meter - Bioburden - No growth on plates analysed by Five Day Bioburden The supplier must have previously supplied a plasmid to this specification that has been used in a similar clinical trial. The supplier must be able to evidence prior success in FDA approvals where their product has been used. The supplier will be required to deliver the product no later than 2 months after contract signature Supplied should follow all relevant legislation applicable to location of operation and State of California, USA

Options: To cover the potential for minor loss or extension of project scope the University may purchase additional orders from the winning supplier via the Negotiated Procedure Without Prior Call For Competition

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-r6ebe6-0000801998
Publication Source
Public Contracts Scotland
Latest Notice
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552953
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
PCS Notice - Website Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33140000 - Medical consumables

Notice Value(s)

Tender Value
£62,000 Under £100K
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£75,135 Under £100K

Notice Dates

Publication Date
31 Mar 20264 months ago
Submission Deadline
1 Jul 2025Expired
Future Notice Date
Not specified
Award Date
14 Aug 20251 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Not Specified
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
University Of Edinburgh
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
EDINBURGH
Postcode
EH1 1HT
Postcode Area
Edinburgh
Country
Scotland
Major Region (ITL 1)
TLM Scotland
Basic Region (ITL 2)
TLM1 East Central Scotland
Small Region (ITL 3)
TLM13 City of Edinburgh
Delivery Location
Not specified
Local Authority
City of Edinburgh
Electoral Ward
City Centre
Westminster Constituency
Edinburgh East and Musselburgh

Supplier Information

Number of Suppliers
1
Supplier Name

Indiana University

Further Information

Notice Documents

  • https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUN532782
    Genome Plasmid - We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles.
  • https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552953
    Genome Plasmid - We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles.

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...